Skip to content6
60 Degrees Pharmaceuticals, Inc.
6
SXTPW60 Degrees Pharmaceuticals, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$303.39K$303.39Kderived+25.6% vs Q4 2024 Net Income-$1.44M-$1.44MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
60 Degrees Pharmaceuticals, Inc. · CIK 1946563 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$182,703+47.9% Operating Incomederived-$1,915,788N/M Operating Cash Flowderived-$1,692,456N/M Free Cash Flowderived-$1,772,337N/M Margins · derivedGross margin60.2%+9.1 pt vs Q4 2024
Operating margin-631.5%+223.2 pt vs Q4 2024
Net margin-474.2%+372.2 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 30, 2026 · 89 d after period end